CoChat

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Blood biomarkers of neuronal damage could facilitate clinical management of and therapeutic development for Huntington's disease. We investigated whether neurofilament light protein NfL (also known as NF-L) in blood is a potential prognostic marker of neurodegeneration in patients with Huntington's disease. METHODS: We did a retrospective analysis of healthy controls and carriers of CAG expansion mutations in HTT participating in the 3-year international TRACK-HD study. We studied associations between NfL concentrations in plasma and clinical and MRI neuroimaging findings, namely cognitive function, motor function, and brain volume (global and regional). We used random effects models to analyse cross-sectional associations at each study visit and to assess changes from baseline, with and without adjustment for age and CAG repeat count. In an independent London-based cohort of 37 participants (23 HTT mutation carriers and 14 controls), we further assessed whether concentrations of NfL in plasma correlated with those in CSF. FINDINGS: Baseline and follow-up plasma samples were available from 97 controls and 201 individuals carrying HTT mutations. Mean concentrations of NfL in plasma at baseline were significantly higher in HTT mutation carriers than in controls (3·63 [SD 0·54] log pg/mL vs 2·68 [0·52] log pg/mL, p<0·0001) and the difference increased from one disease stage to the next. At any given timepoint, NfL concentrations in plasma correlated with clinical and MRI findings. In longitudinal analyses, baseline NfL concentration in plasma also correlated significantly with subsequent decline in cognition (symbol-digit modality test r=-0·374, p<0·0001; Stroop word reading r=-0·248, p=0·0033), total functional capacity (r=-0·289, p=0·0264), and brain atrophy (caudate r=0·178, p=0·0087; whole-brain r=0·602, p<0·0001; grey matter r=0·518, p<0·0001; white matter r=0·588, p<0·0001; and ventricular expansion r=-0·589, p<0·0001). All changes except Stroop word reading and total functional capacity remained significant after adjustment for age and CAG repeat count. In 104 individuals with premanifest Huntington's disease, NfL concentration in plasma at baseline was associated with subsequent clinical onset during the 3-year follow-up period (hazard ratio 3·29 per log pg/mL, 95% CI 1·48-7·34, p=0·0036). Concentrations of NfL in CSF and plasma were correlated in mutation carriers (r=0·868, p<0·0001). INTERPRETATION: NfL in plasma shows promise as a potential prognostic blood biomarker of disease onset and progression in Huntington's disease. FUNDING: Medical Research Council, GlaxoSmithKline, CHDI Foundation, Swedish Research Council, European Research Council, Wallenberg Foundation, and Wolfson Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(17)30124-2

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Associations between NfL concentrations in plasma and disease stage, age, and CAG triplet repeat count (A) Baseline NfL concentrations in plasma, by disease stage. Boxes show first and third quartiles, the central band shows the median, and the whiskers show data within 1·5 IQR of the median. The dots represent outliers. Data were log transformed for comparisons. (B) Associations between NfL concentration in plasma, age, and CAG repeat count, modelled with a polynomial function of age, CAG repeat counts, their squares, and their interactions in 201 HTT mutation carriers and 97 controls. The lines show quadratic fit for all participants with a given CAG repeat count or all controls. Each increase in CAG repeat count was associated with higher and more steeply rising NfL concentrations in plasma. Predicted values are truncated at the vertical inflection point of the parabola. Datapoints for each individual CAG repeat count and for controls are provided in the appendix. HD=Huntington's disease mutation carriers. CAG=mutation carriers' CAG repeat counts.
Figure 1 Associations between NfL concentrations in plasma and disease stage, age, and CAG triplet repeat count (A) Baseline NfL concentrations in plasma, by disease stage. Boxes show first and third quartiles, the central band shows the median, and the whiskers show data within 1·5 IQR of the median. The dots represent outliers. Data were log transformed for comparisons. (B) Associations between NfL concentration in plasma, age, and CAG repeat count, modelled with a polynomial function of age, CAG repeat counts, their squares, and their interactions in 201 HTT mutation carriers and 97 controls. The lines show quadratic fit for all participants with a given CAG repeat count or all controls. Each increase in CAG repeat count was associated with higher and more steeply rising NfL concentrations in plasma. Predicted values are truncated at the vertical inflection point of the parabola. Datapoints for each individual CAG repeat count and for controls are provided in the appendix. HD=Huntington's disease mutation carriers. CAG=mutation carriers' CAG repeat counts.CC BY · PubMed Central
Figure 2 Associations between NfL concentrations in plasma at baseline and cross-sectional measures of cognitive function, motor impairment, and brain volume on MRI (A, B) Association with cognitive scores. (C) Association with motor function. (D–H) Associations with global and regional brain volumes, expressed as percentages of total intracranial volume. UHDRS=Unified Huntington's Disease Rating Scale.
Figure 2 Associations between NfL concentrations in plasma at baseline and cross-sectional measures of cognitive function, motor impairment, and brain volume on MRI (A, B) Association with cognitive scores. (C) Association with motor function. (D–H) Associations with global and regional brain volumes, expressed as percentages of total intracranial volume. UHDRS=Unified Huntington's Disease Rating Scale.CC BY · PubMed Central
Figure 3 Association between baseline NfL concentration in plasma and progression to manifest Huntington's disease in HTT mutation carriers who were premanifest at baseline (A) NfL concentration in plasma at baseline by disease progression status at 3 years. Boxes show first and third quartiles, the central band shows the median, and the whiskers show data within 1·5 IQR of the median. The dots represent outliers. (B) Kaplan-Meier plot showing longitudinal survival in the premanifest state among HTT mutation carriers with NfL concentrations in plasma greater or less than the median. The Cox proportional hazards model is the more sensitive of the two models presented here.
Figure 3 Association between baseline NfL concentration in plasma and progression to manifest Huntington's disease in HTT mutation carriers who were premanifest at baseline (A) NfL concentration in plasma at baseline by disease progression status at 3 years. Boxes show first and third quartiles, the central band shows the median, and the whiskers show data within 1·5 IQR of the median. The dots represent outliers. (B) Kaplan-Meier plot showing longitudinal survival in the premanifest state among HTT mutation carriers with NfL concentrations in plasma greater or less than the median. The Cox proportional hazards model is the more sensitive of the two models presented here.CC BY · PubMed Central
Figure 4 Associations between baseline NfL concentration in plasma and longitudinal change in cognitive, motor, and functional decline and brain atrophy (A, B) Associations with cognitive scores. (C) Association with functional capacity. (D–H) Associations with global and regional brain volumes, expressed as percentages of total intracranial volume. By convention, negative values for change in lateral ventricle volumes indicate ventricular expansion (ie, brain atrophy). SDMT=Symbol-Digit Modality Test Score. SWR=Stroop Word Reading score. UHDRS TFC=Unified Huntington's Disease Rating Scale Total Functional Capacity score. HD=Huntington's disease mutation carriers.
Figure 4 Associations between baseline NfL concentration in plasma and longitudinal change in cognitive, motor, and functional decline and brain atrophy (A, B) Associations with cognitive scores. (C) Association with functional capacity. (D–H) Associations with global and regional brain volumes, expressed as percentages of total intracranial volume. By convention, negative values for change in lateral ventricle volumes indicate ventricular expansion (ie, brain atrophy). SDMT=Symbol-Digit Modality Test Score. SWR=Stroop Word Reading score. UHDRS TFC=Unified Huntington's Disease Rating Scale Total Functional Capacity score. HD=Huntington's disease mutation carriers.CC BY · PubMed Central
Figure 5 NfL concentrations in paired CSF and plasma samples Concentrations in CSF (A) and plasma (B) in HTT mutation carriers and controls. Boxes show first and third quartiles, the central band shows the median, and the whiskers show data within 1·5 IQR of the median. The dots represent outliers. (C) Correlation between NfL concentration in CSF and plasma. HD=Huntington's disease mutation carriers.
Figure 5 NfL concentrations in paired CSF and plasma samples Concentrations in CSF (A) and plasma (B) in HTT mutation carriers and controls. Boxes show first and third quartiles, the central band shows the median, and the whiskers show data within 1·5 IQR of the median. The dots represent outliers. (C) Correlation between NfL concentration in CSF and plasma. HD=Huntington's disease mutation carriers.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 375

Metadata

Authors
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., & Wild, E. J.
Affiliations
  • UCL Queen Square Institute of Neurology (GB)
  • Sahlgrenska University Hospital (SE)
  • University of British Columbia (CA)
  • Leiden University (NL)
  • University of Iowa (US)
Corresponding author
Wild, Edward J
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2017-08
Volume
16
Issue
8
Pages
601-609
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2623948558
Cited by
364
References
27
Citations by year
2026: 28 · 2025: 35 · 2024: 36 · 2023: 44 · 2022: 47 · 2021: 49 · 2020: 39 · 2019: 38 · 2018: 37 · 2017: 11
FWCI
16.74
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • Research Councils UK
  • Knut och Alice Wallenbergs Stiftelse
  • Vetenskapsrådet
  • National Institutes of Health
  • Medical Research Council (MR/M008592/1)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
Keywords
Huntington's disease, neurofilament light chain, blood biomarkers, neurodegeneration, CAG repeat expansion, cognitive decline, brain atrophy, TRACK-HD, prognostic factors, disease stage progression, functional capacity, ventriculomegaly, caudate atrophy, neuroimaging biomarkers
MeSH terms
Huntingtin Protein, Adult, Aged, Atrophy, Brain, Follow-Up Studies, Humans, Huntington Disease, Middle Aged, Retrospective Studies, Biomarkers, Neurofilament Proteins, Disease Progression, Trinucleotide Repeat Expansion, Young Adult, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. https://app.cochat.ai/papers/10.1016/s1474-4422(17)30124-2
The paper
Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D., & Wild, E. J. (2017). Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(17)30124-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.